Cancer Care

 

 
A Randomized Phase II Study of Sequential Biotherapy With Aflibercept and High Dose IL-2 Versus High Dose IL-2 Alone in Patients With Inoperable Stage III or Stage IV Melanoma: Efficacy and Biomarker Study
Principal Investigator (?)
Study Number
W11068
Summary
This randomized phase II clinical trial studies how well aldesleukin with or without
aflibercept works in treating patients with stage III or stage IV melanoma that cannot be
removed by surgery. Aldesleukin may stimulate the white blood cells to kill cancer.
Aflibercept may stop the growth of melanoma by blocking blood flow to the tumor. It is not
yet known whether aldesleukin is more effective with or without aflibercept in treating
melanoma.
Phase (?)
Phase II
Sponsor (?)
Available at the following location(s)

Lebanon

View more details from ClinicalTrials.gov.

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.